Pharmaceutical giant Eli Lilly recently witnessed a significant decline in its stock value after revealing that the demand for its weight loss drugs has negatively impacted their revenue forecast for the coming year. In a surprising turn of events, the company has decided to revise their financial projections downwards, citing a slower-than-expected uptake of their weight loss medications.